Avances en inmunoterapia y terapia regenerativa: herramientas y soluciones para la transición desde la investigación hacia la clínica
En esta jornada abordamos herramientas para inmunoterapia (CAR-T/CAR-NK) y medios especializados para cultivo de células madre mesenquimales con aplicaciones terapéuticas. Soluciones completas para una transición fluida desde la investigación hasta la implementación clínica (medios y reactivos con grado GMP).
Webinars
Powering T-Cell Immunotherapy: Takara Bio’s Solutions from Discovery to Clinic
Diwas Srivastava, PhD, Product Manager for Cell and Gene Therapy at Takara Bio Europe
Diwas walks through the T-cell therapy workflow and explores how Takara Bio’s viral portfolio supports each critical step of the immunotherapy process. Covering everything from cloning the gene of interest and packaging lentiviruses to efficient transduction and T-cell expansion, this talk provides valuable insights for everyone, whether you are a PhD student optimizing experiments at the bench, a researcher advancing translational studies, or a scientist working at the forefront of clinical applications.
Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors
Marta Bort Brusca, Hospital del Mar Research Institute (HMRI) / Vall d'Hebron Institute of Oncology (VHIO)
Marta Bort Brusca is a fourth-year PhD student in a research group led by Joaquín Arribas, currently focused on mechanisms of resistance to targeted therapies and how to overcome this limitation. Her extensive work has led to the generation and characterization of various CARs against specific tumor antigens, as well as the development of antibody-drug conjugates targeting p95HER2.
Tackling Mesenchymal Stem Cell Challenges: Advanced Solutions for Success
Karthi Rajamani, Market strategy manager for drug discovery at Takara Bio Europe.
As the field of regenerative medicine continues to evolve, Mesenchymal Stem Cells (MSCs) emerge as a powerful tool for therapeutic applications, with their extracellular vesicles (EVs) opening new frontiers in drug delivery and regenerative treatments. In this session, Karthi Rajamani, Market Strategy Manager for Drug Discovery at Takara Bio Europe, guides us through:
- The therapeutic potential of MSCs – how they are being used in cell therapy and the exciting applications of their EVs.
- Critical quality attributes for clinical success – ensuring the safety, efficacy, and reproducibility of MSC-based therapies.
- Scaling up production – strategies for efficient MSC expansion in both 2D and 3D culture systems.
- Optimizing EV production – key considerations for generating high-quality EVs from MSCs for clinical and research applications.